In corporate news, Novo Nordisk A/S (NOVOB.C.DX) surged over +7% after the pharmaceutical giant reported better-than-expected Q3 sales of its popular Wegovy weight-loss drug and narrowed its full-year ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

While AstraZeneca and Novo Nordisk are developing similar candidates ... diluted by new issuance like buying many other biotech stocks would. At the end of Q3, it had more than $930 million in cash, ...

In the global pharmaceutical industry, there were eight M&A deals announced in Q3 2024, worth a total value of $1.3bn, according to GlobalData's Deals Database.

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Restaurant Brands International Inc. (T.QSR) (Q3) EPS of $1.30, compared to $1.18 in the prior-year quarter. Novo Nordisk (NYSE: NVO) (Q3) EPS of $3.08, compared to $2.99 in the prior-year quarter.

Bagsværd, Denmark, 7 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated ...

AstraZeneca's price plunge following a fraud investigation in China could be just the time to buy AZN stock as big picture ...

TEVA reports better-than-expected third-quarter results, beating both earnings and sales estimates. However, the stock declines 7%.

According to a March 2023 study from the Bank of America Institute about consumer spending, seniors born in 1964 or earlier ...

Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...